(Total Views: 574)
Posted On: 09/08/2020 11:24:40 AM
Post# of 72444
Looks like one of the researchers, Giovanni Martinelli, was working with Roche on a treatment (RG7356) for AML that hasn’t had much success and has a long list of adverse side effects. I am speculating that a partnership with Roche for Kevetrin is possible since RG7356 isn’t panning out.
“Competing interests
KM is a co-founder of Innovation Pharmaceuticals and he is the inventor of the patent (US 8338454 B2) for the kevetrin molecule used in this study. GM has received honoraria from Novartis, BNS, Roche, Pfizer, Ariad and EMSB. All other authors declare that they have no competing interests.”
Also, this article was submitted December 24, 2019 and accepted June 16, 2020, so again I am speculating that enough time has elapsed for some serious discussions to have transpired that would lead to a partnership.
Lastly, for me, a long time believer and investor of Kevetrin, I am very happy to see that the work at the University of Bologna is bearing some fruit.
“Competing interests
KM is a co-founder of Innovation Pharmaceuticals and he is the inventor of the patent (US 8338454 B2) for the kevetrin molecule used in this study. GM has received honoraria from Novartis, BNS, Roche, Pfizer, Ariad and EMSB. All other authors declare that they have no competing interests.”
Also, this article was submitted December 24, 2019 and accepted June 16, 2020, so again I am speculating that enough time has elapsed for some serious discussions to have transpired that would lead to a partnership.
Lastly, for me, a long time believer and investor of Kevetrin, I am very happy to see that the work at the University of Bologna is bearing some fruit.
(13)
(0)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
